RLAY Relay Therapeutics, Inc.
Research report · from SEC EDGAR · close 2026-07-13
$18.73 -6.4%
$3.59B mkt cap
executive summary
Relay Therapeutics, Inc. (RLAY) is a $3.59B company. Revenue is $15.4M (+53.4% y/y) at a -1801% net margin. It is not yet profitable. Our health score is C (60/100). 3 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$15.4M
+53.4% y/y
⚠Short cash runway
Burning cash with roughly 10 months of runway — a dilutive raise looks likely.
⚠Active dilution shelf
An effective S-3 shelf with 2 prospectus filing(s) in 12 months — shares may be getting sold into the market.
⚠One-sided insider selling
15 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 15
Cash & ST investments
$204.6M
Operating cash flow
-$235.5M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.